Found 33 articles
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials
Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.
Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung
Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.
First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
First Wave BioPharma, Inc. announced that the second patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisPatient dosing expected to begin in mid-February with topline data anticipated by mid-2023
First Wave BioPharma, Inc. today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Arcturus Therapeutics Holdings Inc. today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
First Wave BioPharma, Inc. today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
Aluna Raises $15.3M in Series B Funding To Empower Asthma, COPD and Cystic Fibrosis Patients and Their Doctors
Aluna, the award-winning lung health management platform, announced it has completed a $15.3 million Series B round of financing to continue growing its solution among doctors and patients managing asthma, cystic fibrosis and COPD.
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Krystal Biotech, Inc. announced today that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis (CF).
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
ReCode Therapeutics announced today that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.
Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis
Gensaic, a company that seeks to reimagine gene therapy, announced that it has received an investment from the CF Foundation to develop a gene therapy for Cystic Fibrosis.
Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference
Sionna Therapeutics announced advancement of the company's preclinical and clinical development programs for novel small molecules designed to target the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator protein and complementary mechanisms.
Vertex is kicking off a Phase I trial assessing VX-522, an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease, while SpliSense is targeting a specific mutation.
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Aridis Pharmaceuticals, Inc., a biopharmaceutical company announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis patients.
Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating and Financial Officer
The Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer.
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced the dosing of the first two patients in the Company’s Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis.
Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.
Vertex has made a point over the past decade to make research and development a priority, investing over 70% of its expenses back into it.
Entrinsic Bioscience Steps Closer to Amino Acid Formulation as Therapy for Cystic Fibrosis
Entrinsic Bioscience and its licensee Nuvara Therapeutics announces they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations.
National Jewish Health Pulmonologist Guides Development of Innovative Tool to Help People of Color Screen Their Own Symptoms for Cystic Fibrosis
Cystic fibrosis, a genetic lung disease affecting about 90,000 people worldwide, is most common within the white population, but it affects people of all races and ethnicities.